Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibodies
US11254752B2 · kind B2 · utility
0Cited by
0References
22Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jun 20, 2019 |
| Grant date | Feb 22, 2022 |
| Priority date | — |
| Expiry date | Dec 12, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., ovarian cancer or pancreatic cancer). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to programmed death 1 (PD-1) receptor in combination with a therapeutically effective amount of a bispecific antibody that specifically binds Mucin 16 (MUC16) and CD3.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.